Apolipoprotein proteomics for residual lipid-related risk in coronary heart disease

Background and Aims: Recognition of the importance of conventional lipid measures and the advent of novel lipid-lowering medications have prompted the need for more comprehensive lipid panels to guide use of emerging treatments for prevention of coronary heart disease (CHD). This study assessed the relevance of 13 apolipoproteins for risk of CHD in the PROCARDIS case-control study.